ESTRO meets Asia 2024 - Abstract Book
S188
Interdisciplinary – Head & neck
ESTRO meets Asia 2024
2.de Almeida JR, Truong T, Khan NM, et al. Treatment implications of postoperative chemoradiotherapy for squamous cell carcinoma of the oral cavity with minor and major extranodal extension. Oral Oncol . 2020;110:104845. doi:10.1016/j.oraloncology.2020.104845 2.Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843–50.
359
Digital Poster
Laryngo-esophageal dysfunction-free survival of chemoradiotherapy for cervical esophageal cancer
YUJI MURAKAMI, Ikuno Nishibuchi, Nobuki Imano, Tsuyoshi Katsuta, Junichi Hirokawa, Yasushi Nagata
Radiation oncology, Hiroshima university hospital, Hiroshima, Japan
Purpose/Objective:
Chemoradiotherapy is often the preferred treatment for cervical esophageal cancer due to the invasive nature of surgery. However, the toxicity resulting from chemoradiotherapy frequently impacts the quality of life in terms of swallowing and speech. This study aimed to assess laryngo-esophageal dysfunction-free survival (LEDFS) in patients with cervical esophageal cancer, a measure that has recently been utilized in head and neck cancer research.
Material/Methods:
Patients included underwent definitive chemoradiation therapy with 5-fluorouracil and platinum from 2002 to 2018, had histopathologically confirmed cervical esophageal cancer without distant metastases (except for supraclavicular lymph node metastases). We assessed loco-regional control (LRC), overall survival (OS), laryngectomy free survival (LFS), LEDFS, incidence of metachronous esophageal cancer, and late toxicities. LEDFS events included death, local recurrence, total or partial laryngectomy, tracheostomy, and feeding tube use for more than 2 years. The Kaplan-Meier method and generalized Wilcoxon test were used for survival analysis and comparisons, respectively. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events v5.0.
Results:
Fifty-nine patients (47 men, 12 women; median age 66 years, range 38–83) were included. Clinical stages I–IVB were represented as follows: I (15%), II (9%), III (9%), IVA (10%), and IVB (16%). Treatment modalities included 3D conformal radiotherapy (22 patients) and volumetric modulated arc therapy (37 patients), with a median irradiation dose of 66 Gy (range, 60–70 Gy). All patients received platinum plus 5-fluorouracil chemotherapy. A complete response was observed in 75% of cases, significantly higher in stage I–II (92%) than in stage III–IV (63%; p<0.01). The median follow-up for survivors was 87.5 months. The 5-year LRC, OS, LFS, and LEDFS rates were 54.2%, 48.9%, 50.2%, and 41.9%, respectively. Regarding the laryngo-esophageal dysfunction events, local recurrence, laryngectomy, tracheostomy, and feeding tube use were observed in 17 (29%), 9 (15%), 15 (25%) and 11 (19%) patients, respectively. Prognostic factors for OS included performance status (PS), hypopharyngeal extension, and clinical stage in univariate analysis, with only clinical stage significant in multivariate analysis
Made with FlippingBook flipbook maker